Диссертация (1139713), страница 77
Текст из файла (страница 77)
- 2015. - Vol. 24. - P. 238-252.467. DeVane, C.L What evidence is required for drug exposure to be causally associated with adverse events? Thecase for case reports published in pharmacotherapy / C.L. DeVane // Pharmacotherapy. - 2013. - Vol. 33. - P. 115-117.468.
Douglas, C.M.W. Why orphan drug coverage reimbursement decision-making needs patient and public involvement / C.M.W. Douglas, E. Wilcox, M. Burgess, L.D.Lynd // Health Policy. - 2015. - Vol. 119. - P. 588-596.469. Dylst, P. Demand-side policies to encourage the use of generic medicines: An overview / P. Dylst, A.Vulto, S.Simoens // Expert Review of Pharmacoeconomics & Outcomes Research.
- 2013. - Vol. 13. - P. 59-72.470. Dylst, P. Societal value of generic medicines beyond cost-saving through reduced prices / P. Dylst, A. Vulto, S.Simoens // Expert Review of Pharmacoeconomics and Outcomes Research. - 2014. - Vol. 15. - P. 701-711.471. Economic evaluation of health care. Merging theory with practice / ed. by M.
Drummond, A. McGuire. – NewYork: Oxford University Press, 2007. – P. 72-78.472. Espin, J. External reference pricing. WHO/HAI project on medicine prices and availability [Электронный ресурс] / J. Espin, J. Rovira, А. Olry de Labry. - Geneva/Amsterdam: World Health Organization and Health Action International, 2011. - URL: http://haiweb.org/wp-content/uploads/2015/08/ERP-final-May2011a1.pdf.473. EU Pharmaceutical expenditure forecast, 2012 [Электронный ресурс] / Executive Agency for Health andConsumers-EAHC-European Commission (DG SANCO).
– 2012. URL: http://ec.europa.eu/health/systems_performance_assessment/docs/creativ_ceutical_eu_pharmaceutical_expenditure_forecast.pdf.474. Franken, M. Similarities and differences between five European drug reimbursement systems / M. Franken, M.Le Polain, I. Cleemput, M. Koopmanschap // International Journal of Technology Assessment in Health Care. - 2010. Vol. 28. - P.
349- 357.475. Garone, G. Cost-containment policies in public pharmaceutical spending in the EU [Электронный ресурс] / G.Garone, C. Schwierz, A. Xavier // European Commission (Directorate-General for Economic and Financial Affairs). –Belgium, 2012. - URL: http://ec.europa.eu/economy_finance /publications/economic _paper/2012/pdf/ecp_461_en.pdf.476.
Gautier, S. The cost of adverse drug reactions / S. Gautier et al. // Expert Opinion on Pharmacotherapy. - 2003.- Vol. 4. - P.319-326.477. German pharmacies: Figures, Data, Facts 2010 [Электронный ресурс] / Published by the ABDA – FederalUnion of German Associations of Pharmacists. – Berlin, 2010. - URL: http://www.abda.de/fileadmin/assets/ZDF/ZDF_2010/ABDA_ZDF_2010_engl.pdf.316 478. Gesundheitsausgaben in Deutschland als Anteil am BIP und in Mio. € (absolut und je Einwohner). - URL:http://www.gbebund.de/oowa921intall/servlet/oowa/aw92/dboowasys921.xwdevkit/xwd_init?gbe.isgbetol/xs_start_neu/&p_aid=3&p_aid=88197811&nummer=522&p_sprache=D&p_indsp=-&p_aid=36583640479. Global Pharmaceutical industry and market report [Электронный ресурс] / ABPI.
– URL:http://www.abpi.org.uk/industry-info/knowledge-hub/global-industry/Pages/industry-market-.aspx#fi2.480. Gür Ali, O. How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives / O. Gür Ali, B. Topaler // The European Journal of Health Economics. - 2011. - Vol. 12. - P. 553562.481. Health at a Glance 2015: OECD Indicators [Электронный ресурс] / Paris: OECD Publishing, 2014. - URL:http://www.oecd.org/health/health-systems/health-at-a-glance-19991312.htm482. Helin, M. Content uniformity and stability of nifedipine in extemporaneously compounded oral powders / M.Helin, K. Kontra, T.
Naaranlahti, K. Wallenius // American journal of health–system pharmacy. – 1998. – Vol. 55. - P.1299-1301.483. Henschke, C. Structural changes in the German pharmaceutical market: Price setting mechanisms based on theearly benefit evaluation / C. Henschke, L. Sundmacher, R. Busse // Health Policy. - 2013. - Vol. 109. - P. 263–269.484. International Profiles of Health Care Systems, 2014 [Электронный ресурс] / ed. by E. Mossialos, M. Wenzl,R. Osborn, C. Anderson. – The Commonwealth Fund, 2015.
– New York, 2014. - URL: http://www.commonwealthfund.org/~/media/files/publications/fundreport/2015/jan/1802_mossialos_intl_profiles_2014_v7.pdf.485. Jakovljevic, M.B.. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition / M.B.Jakovljevic, et al. // Expert Review of Pharmacoeconomics & Outcomes Research. - 2015. - Vol. 15 (3).
- P. 1-10.486. Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services // WHOTechnical Report Series. - Geneva: World Health Organization, 2011. - № 961.487. Joint Report on Health Systems, European Economy. Occasional Papers [Электронный ресурс] / EuropeanCommission and the Economic Policy Committee.
– Brussels, 2010. - URL: http://ec.europa.eu/economy_ finance/publications/occasional_paper/2010/pdf/ocp74_en.pdf.488. Kanavos, P. Differences in costs of and access to pharmaceutical products in EU: for the Committee on Environment, Public Health and Food Safety of the European Parliament (ENVY) [Электронный ресурс] / Р. Kanavos etal. // Directorate general for internal policies, Policy Department Economic and Scientific Policy. - Brussels, 2011. URL: http://www.lse.ac.uk/businessAndConsultancy/LSEConsulting/pdf/pharmaceuticals.pdf.489. Kanavos, P. et al. Differences in Costs of and Access to pharmaceutical products in the EU. [Электронный ресурс] / Р.
Kanavos et al. // Directorate general for internal policies, Policy Department Economic and Scientific Policy. Brussels, 2011. - URL: http://www.europarl.europa.eu/RegData/etudes/etudes/join/2011/ 451481/IPOLENVI_ET(2011)451481_EN.pdf.490. Koutkias, V. A Multiagent System for Integrated Detection of Pharmacovigilance Signals [Электронный ресурс] / V.
Koutkias, M.-C. Jaulent // Journal of Medical Systems, Special Issue on Agent-Empowered HealthCare Systems. - 2016. - URL: http://link.springer.com/article/10.1007%2Fs10916-015-0378-0.491. Leyens, L. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up withNew Marketing Authorization Methods / L. Leyens, A. Brand // Public Health Genomics. - 2016. Vol. 19. - P.
187-191.492. Li, H. abc. Revisit what is next for pharmacoeconomics and outcomes research in Asia / H. Li, S. Ngorsuraches// Value in Health Regional Issues. - 2004. - Vol. 7. - P. 118-132.493. Linley, W.G. Reimbursement decisions of the All Wales Medicines Strategy Group: Influence of policy andclinical and economic factors / W.G. Linley, D.A. Hughes // PharmacoEconomics. - 2012. - Vol. 3.
P. 779-794.494. Lu, C.Y Patient access schemes in Asia-pacific markets: Current experience and future potential [Электронный ресурс] / C.Y. Lu et al. // Journal of Pharmaceutical Policy and Practice. - 2015. - URL: http://joppp.biomedcentral.com/articles/10.1186/s40545-014-0019-x.495. Market Review – The European Generic Medicines Markets, 2011. European Generic Medicines Association,Market review / Brussels: European Generic medicines Association; 2011.496. Meier, F. Adverse drug events in patients admitted to an emergency department: An analysis of direct costs / F.Meier et al.
// Pharmacoepidemiology and Drug Safety. - 2015. - Vol. 24. - P. 176-186.497. Mihajlović, J. Reimbursement of targeted cancer therapies within 3 different European health care systems / J.Mihajlović, C. Dolk, K. Tolley, S. Simoens, M.J. Postma // Clinical Therapeutics. - 2015. - Vol.
37 (2). - P. 474–480498. Minh Van, H. Progress toward universal health coverage in ASEAN [Электронный ресурс] / H. Van Minh,N. SuyinPocock, N. Chaiyakunapruk, C. Chhorvann [et al.] // Global Health Action. – 2014. – Vol. 7. - URL:http://www.globalhealthaction.net/index.php/gha/article/view/25856.317 499.
Morrow, N.C. Pharmaceutical Policy Part 2. Pharmaceutical engagement and policy development: A framework for influence [Электронный ресурс] / N.C. Morrow // Journal of Pharmaceutical Policy and Practice. - 2015. URL: http://joppp.biomedcentral.com/articles/10.1186/s40545-015-0026-6.500.
Naik, P. Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations / P. Naik et al. // Therapeutic Innovation and Regulatory Science. - 2015. - Vol. 49. - P. 840-851.501. Orphan medicines in numbers: The success of ten years of orphan legislation (EMA/279601/2010) // EuropeanMedicinesAgency.URL:http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/05/WC500090812.pdf.502.
OTC Distribution in Europe The New Global Agenda - New 2016 Edition An in-depth strategic 20 countrystudy of Europe’s. Major Markets: OTC Bulletin [Электронный ресурс] // James Dudley Management, 2016. - URL:http://james-dudley.co.uk/market-reports/otc-distribution-in-europe503. Persson, U. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing / U.
Persson, J. Svensson, B. Pettersson // Publication: Applied Health Economics and Health Policy. - 2012.- Vol. 10. - P. 217-225.504. Pharmaceutical Prices: Why are there differences between Member States [Электронный ресурс] / Explanatory Memorandum EUCOPE. - URL: ttp://www.eucope.org/en/files/2012/10/EUCOPE-IRP.pdf.505. Pharma-Daten 2015. BPI.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
